This biotechnology company develops a platform technology to produce plant-derived proteins for improved nutrition and health. They offer low-carbon footprint, plant-based protein solutions, enabling the food and beverage industry to meet the demand for sustainable andishing healthy protein alternatives.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods of producing recombinant proteins for medicine and biotechnology, such as bacterial, yeast, and mammalian cell-culture expression systems, can be expensive, have a high carbon footprint, and risk contamination from animal, human, or microbial by-products. Sourcing proteins directly from natural sources is often impractical and cannot achieve therapeutic scale.
Solution
ExpressTec has developed a patented, plant-based platform that uses rice plants as bioreactors to produce recombinant proteins. The plants harness sunlight, soil, water, and air to manufacture desired proteins, which naturally concentrate within the rice-seed endosperm for easy harvest and purification. This system offers commercial-scale product yields in a eukaryotic host background, without contamination from animal, human, or microbial by-products. The ExpressTec platform enables the development of new biotherapeutics, novel vaccines, cell culture media components for cell therapy, gene therapy and vaccine applications, and enzymes.
Target Audience
The primary customers are biopharmaceutical companies, cell therapy companies, and vaccine developers seeking a cost-effective and scalable method for producing recombinant proteins and cell-culture media components.
Features
- Patented plant-based technology using rice plants as bioreactors
- High protein yields compared to other plant-based systems
- Production process free of contamination from animal, human, or microbial origin
- Suitable for expression of multi-subunit molecules, monoclonal antibodies, fusion proteins, and enzymes
- Reduced carbon footprint compared to traditional bioreactors
- Ability to produce orally available proteins, such as those found in human colostrum and breastmilk
- Extensive intellectual property portfolio with over 100 issued patents and exclusive licenses